We are live on ! Find out more
HALO icon

Halozyme

198 hedge funds and large institutions have $2.48B invested in Halozyme in 2017 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 72 increasing their positions, 54 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

229% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 14

148% more call options, than puts

Call options by funds: $62M | Put options by funds: $24.9M

33% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 54

19% more funds holding

Funds holding: 166198 (+32)

18% more capital invested

Capital invested by funds: $2.11B → $2.48B (+$372M)

0.46% more ownership

Funds ownership: 85.64%86.1% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
198
Holders Change
+32
Holders Change %
+19.28%
% of All Funds
4.48%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
46
Increased
72
Reduced
54
Closed
14
Calls
$62M
Puts
$24.9M
Net Calls
+$37M
Net Calls Change
-$19.7M

HALO Hedge Fund Activity: Q4 2017 in Review

198 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q4 2017, worth a combined $2.48B — up 18% from $2.11B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new HALO positions and 14 closed out — a net gain of 32 holders — while 72 added to existing stakes and 54 trimmed.

The largest buyer was Vanguard Group, adding an estimated $22.2M. The largest seller was Senzar Asset Management, cutting an estimated $60.5M.

  • 198 institutional investors held Halozyme (HALO) as of Q4 2017, up from 166 in Q3 2017.
  • Funds reported $2.48B of Halozyme stock for Q4 2017, up 18% quarter-over-quarter.
  • 46 funds opened new Halozyme positions in Q4 2017 and 14 closed out, a net change of +32 holders.
  • The largest Halozyme buyer in Q4 2017 was Vanguard Group, an estimated $22.2M added.
  • The largest Halozyme seller in Q4 2017 was Senzar Asset Management, an estimated $60.5M sold.

Based on aggregated 13F filings for Q4 2017.